New systemic drugs in the treatment of gastrointestinal cancer.
Paclitaxel has shown a significant activity on esophageal cancer in a phase II trial. Irinotecan has established the single-agent efficacy on both gastric and colorectal cancer. Docetaxel has attained a significant activity on advanced gastric cancer and a 29% response rate on pancreatic cancer in a phase II trial. Tomudex has shown comparable activity to leucovorin and 5-fluorouracil in colorectal cancer.
Ogawa
M
M
Aichi Cancer Center, Nagoya, Japan.
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D000077146:Irinotecan; D017239:Paclitaxel / Q000031:analogs & derivatives / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D043823:Taxoids; D013876:Thiophenes / Q000627:therapeutic use; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors
D000972:Antineoplastic Agents, Phytogenic; D011799:Quinazolines; D043823:Taxoids; D013876:Thiophenes; D000077143:Docetaxel; D000077146:Irinotecan; D013940:Thymidylate Synthase; C068874:raltitrexed; D017239:Paclitaxel; D002166:Camptothecin